Immuneering Corporation, a Cambridge, MA-based developer of new medicines by leveraging bioinformatics, closed its Series A round at a total of $20m.
The round was led by Boxcar PMJ LLC.
The company intends to use the funds to advance its programs towards the clinic in cancer cachexia, next-generation KRAS inhibition, and the RAF-MEK pathway, while further developing its Disease Cancelling Technology and computational platforms.
Led by Ben Zeskind, Ph.D., MBA, co-founder and chief executive officer, Immuneering leverages bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Concurrent with its internal programs, the company provides computational biology services to pharmaceutical and biotechnology companies.